Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Capital Expenditures (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Capital Expenditures data on record, last reported at $50000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 91.9% year-over-year to $50000.0; the TTM value through Dec 2025 reached $50000.0, down 94.48%, while the annual FY2025 figure was $50000.0, 94.48% down from the prior year.
  • Capital Expenditures reached $50000.0 in Q4 2025 per FHTX's latest filing, up from -$28000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.0 million in Q2 2021 and bottomed at -$1.2 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $290210.5, with a median of $230000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 236.25% in 2022, then crashed 528.25% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $80000.0 in 2021, then soared by 236.25% to $269000.0 in 2022, then plummeted by 528.25% to -$1.2 million in 2023, then surged by 153.56% to $617000.0 in 2024, then plummeted by 91.9% to $50000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $50000.0 in Q4 2025, -$28000.0 in Q2 2025, and $28000.0 in Q1 2025.